Year: 2006
Type: conference-abstract
Abstract: IL-6 is a pleiotropic cytokine involved in both the initiation and the maintenance of the inflammatory and immunologic responses in certain autoimmune diseases. Blocking of these two complementary functions of IL-6 may confer additive, or even unique, benefits to the patient. The levels of both IL-6 and its soluble receptor (sIL-6Ralpha) are elevated to various degrees in many rheumatic diseases. IL-6 blockade has been shown to be beneficial both in experimental models and in human disease, and inhibition of IL-6 signaling with a molecule such as tocilizumab could prevent or reverse some of the complications typically associated with rheumatic diseases.
Source: Arthritis Research & Therapy
DOI: 10.1186/ar1918
Author: Peter E Lipsky
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,690
OpenAlex ID: W1853637197